Trial Condition(s):

Multiple Sclerosis, Clinically Isolated System

Betaferon® regulatory Post-Marketing Surveillance

Bayer Identifier:

14839

ClinicalTrials.gov Identifier:

NCT01414816

EudraCT Number:

Not Available

Study Completed

Trial Purpose

To identify problems/questions about following items in the clinical practice using Betaferon
(1) Unknown adverse event (especially serious adverse event)
(2) Identification of adverse event occurred in the real practice
(3) Factors that may affect the safety of drug
(4) Factors that may affect the effectiveness of the drug

Inclusion Criteria
- Patients with diagnosis of MS or CIS and decision taken by the physician to prescribe Betaferon 
- Patients who have not participated in Betaferon regulatory Post Marketing Surveillance before.
Exclusion Criteria
- Exclusion criteria must be read in conjunction with local product information

Trial Summary

Enrollment Goal
355
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Betaseron (Interferon beta-1b, BAY86-5046)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, South Korea

Status
Completed
 

Trial Design